Objective: The aim was to study the neuroprotective effect of quercetin in the animal model of neurodegeneration.
Materials and Methods: Quercetin (3,5,7,3',4'-pentahydroxy flavones) is a potential compound having both anti-inflammatory and anti-oxidant
properties with low gastric and cardiac side effect. Different Cyclooxygenase (COX-2) inhibitors such as nimesulide, refecoxib and celecoxib have
been proved to have their neuroprotective action in different animal models of neurodegenerative disorders, but they are burdened with high toxicity.
Different neurodegenerative models like haloperidol-induced catalepsy, reserpine induced vacuous chewing movements and 1-Methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) induced neurodegeneration were evaluated with levadopa at a dose of (30 mg/kg i.p.) and quercetin at a dose of
(25 mg/kg, p.o.) as standard and test drugs respectively.
Results: In the haloperidol-induced catalepsy model the increased cataleptic score was significantly reduced with both the standard drug levodopa
and the test drug quercetin. The increased frequencies of vacuous chewing movements on administration of reserpine were reversed with the
treatment of quercetin. The reduced actophotometer activity score due to reserpine was significantly reversed by quercetin. The decreased level of
lipid per-oxidation and increased glutathione concentration by the administration of quercetin that reversed the toxicity of MPTP.
Conclusion: Quercetin is a potential compound having both anti-inflammatory and anti-oxidant properties. These effects of enlights the
pharmacodynamic pathway of neuroprotective properties of quercetin in animal model study.

Keywords: Catalepsy, Cyclooxygenases, Neuroprotection, Quercetin.


Lee JM, Sancheti S, Noh CI, Cho DW, Choi JH. Ameliorative effect

of novel vitamin formula with herbal extracts on scopolamine-induced

Alzheimer’s disease. Asian J Pharm Clin Res 2013;6(2):175-9.

Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E.

Staging of brain pathology related to sporadic Parkinson’s disease.

Neurobiol Aging 2003;24:197-211.

McGeer PL, McGeer EG. Inflammation and the degenerative diseases

of aging. Ann N Y Acad Sci 2004;1035:104-16.

McGeer PL, McGeer EG. NSAIDs and Alzheimer disease:

Epidemiological, animal model and clinical studies. Neurobiol Aging


Ahmad M, Zhang Y, Liu H, Rose ME, Graham SH. Prolonged

opportunity for neuroprotection in experimental stroke with selective

blockade of cyclooxygenase-2 activity. Brain Res 2009;1279:168-73.

Hyo JL, Hua L. Quercetin from Siegesbeckia glabrescens inhibits the

expression of COX-2 through the suppression of NF-kB activation in

microglia. Biomol Ther 2011;19:27-32.

Mayee R, Thosar R. Evalution of antiasthmatic activity of Calotropis

gigantea roots. Asian J Pharm Clin Res 2011;4(2):330-5.

Klemm WR. Evidence for a cholinergic role in haloperidol-induced

catalepsy. Psychopharmacology (Berl) 1985;85(2):139-42.

Naidu PS, Singh A, Kulkarni SK. Effect of Withania somnifera root

extract on reserpine-induced orofacial dyskinesia and cognitive

dysfunction. Phytother Res 2006;20(2):140-6.

Grimm JW, Kruzich PJ, See RE. Emergence of oral and locomotor

activity in chronic haloperidol-treated rats following cortical

N-methyl-D-aspartate stimulation. Pharmacol Biochem Behav


Wang T, Pei Z, Zhang W, Liu B, Langenbach R, Lee C, et al.

MPP+-induced COX-2 activation and subsequent dopaminergic

neurodegeneration. FASEB J 2005;19(9):1134-6.

Huong NT, Matsumoto K, Kasai R, Yamasaki K, Watanabe H. In vitro

antioxidant activity of Vietnamese ginseng saponin and its components.

Biol Pharm Bull 1998;21(9):978-81.

Chance B, Maehly AC. Assay catalases and peroxidise. Methods

Enzyml 1955;2:764-8.

Ellman G, Lysko H. A precise method for the determination of whole

blood and plasma sulfhydryl groups. Anal Biochem 1979;93(1):98-102.

Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF.

Expression of a mitogen-inducible cyclooxygenase in brain

neurons: regulation by synaptic activity and glucocorticoids. Neuron


Oka A, Takashima S. Induction of cyclo-oxygenase 2 in brains of

patients with Down’s syndrome and dementia of Alzheimer type:

Specific localization in affected neurones and axons. Neuroreport


Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased

in frontal cortex of Alzheimer’s disease brain. Neuroscience


Naidu PS, Singh A, Kulkarni SK. Carvedilol attenuates neurolepticinduced

orofacial dyskinesia: Possible antioxidant mechanisms. Br J

Pharmacol 2002;136(2):193-200.

Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymesCOX-1 and COX-2 provide neuroprotection in the MPTP-mouse model

of Parkinson’s disease. Synapse 2001;39(2):167-74.

Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, et al.

Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1,

, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in

the substantia nigra. Neurosci Lett 2002;329(3):354-8.

Figueiredo-Pereira ME, Li Z, Jansen M, Rockwell P. N-acetylcysteine

and celecoxib lessen cadmium cytotoxicity which is associated with

cyclooxygenase-2 up-regulation in mouse neuronal cells. J Biol Chem


Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S,

et al. Cyclooxygenase-2 is instrumental in Parkinson’s disease

neurodegeneration. Proc Natl Acad Sci U S A 2003;100(9):5473-8.

Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS,

et al. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-

tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration

in C57BL/6 mice. Brain Res 2003;964(2):288-94.

Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, et al.

Involvement of interferon-gamma in microglial-mediated loss of

dopaminergic neurons. J Neurosci 2007;27(12):3328-37.

Lipton SA, Rosenberg PA. Excitatory amino acids as a final common

pathway for neurologic disorders. N Engl J Med 1994;330(9):613-22.

Kulkarni SK, Jain NK, Singh A. Cyclooxygenase isoenzymes and

newer therapeutic potential for selective COX-2 inhibitors. Methods

Find Exp Clin Pharmacol 2000;22(5):291-8.

Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: Structural,

cellular, and molecular biology. Annu Rev Biochem 2000;69:145-82.

Hurley SD, O’Banion MK, Song DD, Arana FS, Olschowka JA, Haber

SN. Microglial response is poorly correlated with neurodegeneration

following chronic, low-dose MPTP administration in monkeys. Exp

Neurol 2003;184(2):659-68.

Morrow JD, Roberts LJ 2nd. Lipid-derived autocoids: Eicosanoids and

platelet activating factor. In: Hardman JG, Limbird LE, Gilman AG,

editors. Goodman & Gilman’s The Pharmcological Basis of Therapeutics.

th ed., Ch. 26. New York: McGraw-Hill; 2001. p. 669-87.

Abdel-Halim MS, Lundén I, Cseh G, Anggård E. Prostaglandin profiles

in nervous tissue and blood vessels of the brain of various animals.

Prostaglandins 1980;19(2):249-58.

Neisewander JL, Castañeda E, Davis DA. Dose-dependent differences

in the development of reserpine-induced oral dyskinesia in rats:

Support for a model of tardive dyskinesia. Psychopharmacology (Berl)


Neisewander JL, Castañeda E, Davis DA, Elson HJ, Sussman AN.

Effects of amphetamine and 6-hydroxydopamine lesions on reserpineinduced

oral dyskinesia. Eur J Pharmacol 1996;305(1-3):13-21.

Nade VS, Dwivedi S, Kawale LA, Upasani CD, Yadav AV. Effect of

Hibiscus rosa sinensis on reserpine-induced neurobehavioral and

biochemical alterations in rats. Indian J Exp Biol 2009;47(7):559-63.



How to Cite

PANY, S., A. PAL, and P. K. SAHU. “NEUROPROTECTIVE EFFECT OF QUERCETIN IN NEUROTOXICITY INDUCED RATS: ROLE OF NEUROINFLAMMATION IN NEURODEGENERATION”. Asian Journal of Pharmaceutical and Clinical Research, vol. 7, no. 4, Sept. 2014, pp. 152-6,



Original Article(s)